Constitutive MTOR Activation in TSC Mutants Sensitizes Cells to Energy Starvation and Genomic Damage Via P53

Overview

Journal EMBO J

Specialties Biotechnology
Molecular Biology

Date 2007 Oct 27

PMID 17962806

Citations 102

Authors

Chung-Han Lee

Ken Inoki

Magdalena Karbowniczek

Emmanuel Petroulakis

Nahum Sonenberg

Elizabeth Petri Henske

Kun-Liang Guan

Affiliations

Soon will be listed here.

Abstract

Miscoordination of growth and proliferation with the cellular stress response can lead to tumorigenesis. Mammalian target of rapamycin (mTOR), a central cell growth controller, is highly activated in some malignant neoplasms, and its clinical implications are under extensive investigation. We show that constitutive mTOR activity amplifies p53 activation, in vitro and in vivo, by stimulating p53 translation. Thus, loss of TSC1 or TSC2, the negative regulators of mTOR, results in dramatic accumulation of p53 and apoptosis in response to stress conditions. In other words, the inactivation of mTOR prevents cell death by nutrient stress and genomic damage via p53. Consistently, we also show that p53 is elevated in TSC tumors, which rarely become malignant. The coordinated relationship between mTOR and p53 during cellular stress provides a possible explanation for the benign nature of hamartoma syndromes, including TSC. Clinically, this also suggests that the efficacy of mTOR inhibitors in anti-neoplastic therapy may also depend on p53 status, and mTOR inhibitors may antagonize the effects of genotoxic chemotherapeutics.

Citing Articles

mTORC1 regulates cell survival under glucose starvation through 4EBP1/2-mediated translational reprogramming of fatty acid metabolism.

Levy T, Voeltzke K, Hruby L, Alasad K, Bas Z, Snaebjornsson M Nat Commun. 2024; 15(1):4083.

PMID: 38744825 PMC: 11094136. DOI: 10.1038/s41467-024-48386-y.

Activation of mTOR signaling in adult lung microvascular progenitor cells accelerates lung aging.

Mason E, Menon S, Schneider B, Gaskill C, Dawson M, Moore C J Clin Invest. 2023; 133(24).

PMID: 37874650 PMC: 10721153. DOI: 10.1172/JCI171430.

MicroRNA Expression Profile in TSC Cell Lines and the Impact of mTOR Inhibitor.

Pawlik B, Grabia S, Smyczynska U, Fendler W, Drozdz I, Liszewska E Int J Mol Sci. 2022; 23(22).

PMID: 36430972 PMC: 9694073. DOI: 10.3390/ijms232214493.

Global cellular response to chemical perturbation of PLK4 activity and abnormal centrosome number.

Tkach J, Philip R, Sharma A, Strecker J, Durocher D, Pelletier L Elife. 2022; 11.

PMID: 35758262 PMC: 9236612. DOI: 10.7554/eLife.73944.

Age-Related Lysosomal Dysfunctions.

Guerrero-Navarro L, Jansen-Durr P, Cavinato M Cells. 2022; 11(12).

PMID: 35741106 PMC: 9221958. DOI: 10.3390/cells11121977.

References

Kim J, Lee C, Bonifant C, Ressom H, Waldman T . Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol. 2006; 27(2):662-77. PMC: 1800819. DOI: 10.1128/MCB.00537-06. View

Wataya-Kaneda M, Kaneda Y, Hino O, Adachi H, Hirayama Y, Seyama K . Cells derived from tuberous sclerosis show a prolonged S phase of the cell cycle and increased apoptosis. Arch Dermatol Res. 2002; 293(9):460-9. DOI: 10.1007/s004030100259. View

Ghosh S, Tergaonkar V, Rothlin C, Correa R, Bottero V, Bist P . Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival. Cancer Cell. 2006; 10(3):215-26. DOI: 10.1016/j.ccr.2006.08.007. View

Tee A, Manning B, Roux P, Cantley L, Blenis J . Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003; 13(15):1259-68. DOI: 10.1016/s0960-9822(03)00506-2. View

Shaw R, Bardeesy N, Manning B, Lopez L, Kosmatka M, DePinho R . The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004; 6(1):91-9. DOI: 10.1016/j.ccr.2004.06.007. View

Ray P, Grover R, Das S . Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep. 2006; 7(4):404-10. PMC: 1456917. DOI: 10.1038/sj.embor.7400623. View

Beranek D . Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat Res. 1990; 231(1):11-30. DOI: 10.1016/0027-5107(90)90173-2. View

Inoki K, Li Y, Zhu T, Wu J, Guan K . TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002; 4(9):648-57. DOI: 10.1038/ncb839. View

Ali S, Sabatini D . Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. J Biol Chem. 2005; 280(20):19445-8. DOI: 10.1074/jbc.C500125200. View

10.

Kahn B, Alquier T, Carling D, Grahame Hardie D . AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005; 1(1):15-25. DOI: 10.1016/j.cmet.2004.12.003. View

11.

Sarbassov D, Ali S, Kim D, Guertin D, Latek R, Erdjument-Bromage H . Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004; 14(14):1296-302. DOI: 10.1016/j.cub.2004.06.054. View

12.

Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, OReilly T . The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005; 120(6):747-59. DOI: 10.1016/j.cell.2004.12.040. View

13.

Hresko R, Mueckler M . mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005; 280(49):40406-16. DOI: 10.1074/jbc.M508361200. View

14.

Henske E, Neumann H, Scheithauer B, Herbst E, Short M, Kwiatkowski D . Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer. 1995; 13(4):295-8. DOI: 10.1002/gcc.2870130411. View

15.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J . Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108(8):1167-74. PMC: 209533. DOI: 10.1172/JCI13505. View

16.

Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg M, Hall A . Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004; 6(11):1122-8. DOI: 10.1038/ncb1183. View

17.

Castedo M, Ferri K, Blanco J, Roumier T, Larochette N, Barretina J . Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-associated protein-mediated p53 phosphorylation. J Exp Med. 2001; 194(8):1097-110. PMC: 2193513. DOI: 10.1084/jem.194.8.1097. View

18.

Li Y, Inoki K, Guan K . Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol Cell Biol. 2004; 24(18):7965-75. PMC: 515062. DOI: 10.1128/MCB.24.18.7965-7975.2004. View

19.

Zhang H, Cicchetti G, Onda H, Koon H, Asrican K, Bajraszewski N . Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest. 2003; 112(8):1223-33. PMC: 213485. DOI: 10.1172/JCI17222. View

20.

Duckett D, Bronstein S, Taya Y, Modrich P . hMutSalpha- and hMutLalpha-dependent phosphorylation of p53 in response to DNA methylator damage. Proc Natl Acad Sci U S A. 1999; 96(22):12384-8. PMC: 22926. DOI: 10.1073/pnas.96.22.12384. View